Should I buy or sell LifeMD stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LifeMD in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LFMD shares. View LFMD analyst ratings or view top-rated stocks .

What is LifeMD's stock price target for 2024?

5 brokers have issued 1-year target prices for LifeMD's shares. Their LFMD share price targets range from $7.00 to $13.00. On average, they anticipate the company's share price to reach $10.20 in the next twelve months. This suggests a possible upside of 5.2% from the stock's current price. View analysts price targets for LFMD or view top-rated stocks among Wall Street analysts .

How have LFMD shares performed in 2024?

LifeMD's stock was trading at $8.29 at the start of the year. Since then, LFMD stock has increased by 17.0% and is now trading at $9.70. View the best growth stocks for 2024 here .

Are investors shorting LifeMD?

LifeMD saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 2,650,000 shares, an increase of 37.3% from the March 15th total of 1,930,000 shares. Based on an average trading volume of 762,800 shares, the short-interest ratio is currently 3.5 days. Currently, 8.6% of the company's shares are short sold. View LifeMD's Short Interest .

When is LifeMD's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our LFMD earnings forecast .

How were LifeMD's earnings last quarter?

LifeMD, Inc. (NASDAQ:LFMD) posted its quarterly earnings data on Monday, March, 11th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. The company earned $44.86 million during the quarter, compared to analysts' expectations of $40.65 million.

What ETF holds LifeMD's stock?

Invesco Dorsey Wright Healthcare Momentum ETF holds 140,399 shares of LFMD stock, representing 0.98% of its portfolio.

What guidance has LifeMD issued on next quarter's earnings?

LifeMD updated its first quarter 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $42.0 million-$43.0 million, compared to the consensus revenue estimate of $42.5 million.

How do I buy shares of LifeMD?

Shares of LFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:LFMD

LifeMD (LFMD) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free LFMD Stock Alerts

$9.70

-0.51 (-5.00%)

(As of 04/19/2024 ET)

Compare

Today's Range: $9.56
▼
$10.25
50-Day Range: $6.00
▼
$11.53
52-Week Range: $1.40
▼
$12.01

Volume: 493,280 shs
Average Volume: 824,144 shs
Market Capitalization: $391.59 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $10.20

Get LifeMD alerts:

LifeMD MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 5.2% Upside
$10.20 Price Target
Short Interest: Bearish
8.57% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.14) to ($0.31) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.21 out of 5 stars

Medical Sector

891st out of 911 stocks

Offices & Clinics Of Medical Doctors Industry

7th out of 7 stocks

1.5

Analyst's Opinion

Consensus Rating
LifeMD has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
LifeMD has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
8.57% of the float of LifeMD has been sold short.
Short Interest Ratio / Days to Cover
LifeMD has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in LifeMD has recently increased by 37.31%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
LifeMD does not currently pay a dividend.
Dividend Growth
LifeMD does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LFMD.

2.6

News and Social Media Coverage

News Sentiment
LifeMD has a news sentiment score of 1.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for LifeMD this week, compared to 1 article on an average week.
Search Interest
Only 16 people have searched for LFMD on MarketBeat in the last 30 days. This is a decrease of -64% compared to the previous 30 days.
MarketBeat Follows
Only 7 people have added LifeMD to their MarketBeat watchlist in the last 30 days. This is a decrease of -53% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, LifeMD insiders have not sold or bought any company stock.
Percentage Held by Insiders
18.89% of the stock of LifeMD is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 35.52% of the stock of LifeMD is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for LifeMD are expected to decrease in the coming year, from ($0.14) to ($0.31) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of LifeMD is -13.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of LifeMD is -13.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
LifeMD has a P/B Ratio of 64.67. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Crypto 101 Media

SHOCKING Crypto Leak…

A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.

Claim your free seat by clicking here now.

About LifeMD Stock (NASDAQ:LFMD)

LifeMD, Inc. operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies. It also provides LifeMD PC, a direct-to-consumer virtual primary care which includes 24/7 access to a provider for their primary care, urgent care, and chronic care needs; and offers virtual consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, and more. In addition, the company offers PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents; ResumeBuild which provides digital resume and cover letter services; SignSimpli, a digital signature platform; and LegalSimpli, a provider of legal forms for consumers and small businesses. It sells its products directly to consumers and through e-commerce platforms, as well as through third party partner channels. The company was formerly known as Conversion Labs, Inc. and changed its name to LifeMD, Inc. in February 2021. LifeMD, Inc. was incorporated in 1994 and is headquartered in New York, New York.

LFMD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LFMD Stock News Headlines

March 19, 2024 | marketbeat.com

LifeMD Shares Come Back to Life on GLP-1 Business Growth

LifeMD Inc. NASDAQ: LFMD provides telehealth services to consumers in the United States. The medical sector company operates many telehealth brands, including men's telehealth brands RexMD and ShapiroMD, NavaMD female dermatology telehealth, Cleared Allergy Clinic, and LifeMD Primary Care.

March 19, 2024 | marketbeat.com

LifeMD Shares Come Back to Life on GLP-1 Business Growth

LifeMD stock is surging as the company is riding the GLP-1 trend to double-digit revenue growth and projections for 67% earnings growth in 2024

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

April 12, 2024 | markets.businessinsider.com

Buy Rating Affirmed for LifeMD Amid Favorable Legal Outlook and Competitive Strengths

April 9, 2024 | markets.businessinsider.com

Alkermes' Sleeping Disorder Studies' Data Look Excellent, Analyst Says

March 25, 2024 | globenewswire.com

LifeMD to Participate in the 23rd Annual Needham Virtual Healthcare Conference

March 13, 2024 | finance.yahoo.com

LifeMD Full Year 2023 Earnings: Beats Expectations

March 12, 2024 | markets.businessinsider.com

LifeMD Poised for Growth: Strong Q4 Performance and Positive FY24 Outlook Reinforce Buy Rating

April 19, 2024 | Altimetry (Ad)

Secret Bull Market Starts in This Unusual Sector

March 11, 2024 | marketwatch.com

LifeMD Shares Jump on Strong 4Q

March 11, 2024 | globenewswire.com

LifeMD Reports Fourth Quarter 2023 Results

March 10, 2024 | markets.businessinsider.com

Here's what to expect from LifeMD's earnings

March 5, 2024 | realmoney.thestreet.com

Get Your Shopping List Ready: Here's How to Buy Pullbacks

February 27, 2024 | finance.yahoo.com

LifeMD Insiders Placed Bullish Bets Worth US$1.24m

February 26, 2024 | finance.yahoo.com

LifeMD to Report Fourth Quarter 2023 Financial Results on March 11

February 17, 2024 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: LifeMD (LFMD), Tandem Diabetes Care (TNDM)

February 15, 2024 | finance.yahoo.com

LifeMD to Participate in Upcoming Investor Conferences and Webinar

February 14, 2024 | realmoney.thestreet.com

It's a Stock Pickers' Market and 4 of My Own Were Up More Than 10% Wednesday

February 6, 2024 | realmoney.thestreet.com

I'm Adding This Small-Cap Stock to My Watchlist Amid Rotational Action

February 5, 2024 | msn.com

Medical Cannabis Pioneer cbdMD Secures $1.2M To Fund Rollout Of Functional Mushroom Products

January 31, 2024 | finance.yahoo.com

LifeMD to Participate in the 11th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

January 31, 2024 | finance.yahoo.com

LifeMD (NASDAQ:LFMD) shareholders have earned a 49% CAGR over the last five years

January 23, 2024 | realmoney.thestreet.com

Four Small-Caps and One Very Large-Cap I'm Trading as Earnings Season Heats Up

January 18, 2024 | finance.yahoo.com

LifeMD to Participate in the Maxim Group 2024 Healthcare IT Virtual Conference

January 11, 2024 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: LifeMD (LFMD) and Coherus Biosciences (CHRS)

January 10, 2024 | forbes.com

Best Iodine Supplements Of 2024

January 8, 2024 | finance.yahoo.com

LifeMD Provides 2024 Financial Guidance

See More Headlines

Receive LFMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LifeMD and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/11/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Offices & clinics of medical doctors
Sub-Industry: N/A
Current Symbol: NASDAQ:LFMD
CUSIP: N/A
CIK: 948320
Web: www.lifemd.com
Phone: (866) 351-5907
Fax: N/A
Employees: 207
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $10.20
High Stock Price Target: $13.00
Low Stock Price Target: $7.00
Potential Upside/Downside: +5.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.70)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-20,600,000.00
Net Margins: -14.01%
Pretax Margin: -11.41%
Return on Equity: N/A
Return on Assets: -50.74%

Debt

Debt-to-Equity Ratio: 3.22
Current Ratio: 1.22
Quick Ratio: 1.15

Sales & Book Value

Annual Sales: $152.55 million
Price / Sales: 2.57
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.15 per share
Price / Book: 64.67

Miscellaneous

Outstanding Shares: 40,370,000
Free Float: 32,741,000
Market Cap: $391.59 million
Optionable: Optionable
Beta: 1.43

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Mr. Justin Schreiber (Age 41)
Chairman & CEO
Comp: $255k
Mr. Marc Benathen (Age 43)
Chief Financial Officer
Comp: $378.75k
Mr. Eric H. Yecies (Age 46)
Chief Legal Officer, General Counsel & Secretary
Comp: $332k
Ms. Maria E. Stan CPA (Age 49)
Controller & Principal Accounting Officer
Mr. Dennis Wijnker (Age 48)
Chief Technology Officer
Mr. Shane Biffar
Chief Compliance Officer & Deputy General Counsel
Ms. Jessica Friedeman (Age 40)
Chief Marketing Officer
Mr. Stefan Galluppi (Age 37)
Chief Innovation Officer
Comp: $165k
Mr. Nicholas P. Alvarez (Age 42)
Chief Acquisition Officer & Head of Customer Acquisition
Comp: $141.11k
Mr. Varun Pathak
Chief Software Engineer & Co-Founder of PDF Simpli

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LFMD Stock Analysis - Frequently Asked Questions

Should I buy or sell LifeMD stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for LifeMD in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LFMD shares.
View LFMD analyst ratings or view top-rated stocks.
What is LifeMD's stock price target for 2024?: 5 brokers have issued 1-year target prices for LifeMD's shares. Their LFMD share price targets range from $7.00 to $13.00. On average, they anticipate the company's share price to reach $10.20 in the next twelve months. This suggests a possible upside of 5.2% from the stock's current price.
View analysts price targets for LFMD or view top-rated stocks among Wall Street analysts.
How have LFMD shares performed in 2024?: LifeMD's stock was trading at $8.29 at the start of the year. Since then, LFMD stock has increased by 17.0% and is now trading at $9.70.
View the best growth stocks for 2024 here.
Are investors shorting LifeMD?: LifeMD saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 2,650,000 shares, an increase of 37.3% from the March 15th total of 1,930,000 shares. Based on an average trading volume of 762,800 shares, the short-interest ratio is currently 3.5 days. Currently, 8.6% of the company's shares are short sold.
View LifeMD's Short Interest.
When is LifeMD's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our LFMD earnings forecast.

How were LifeMD's earnings last quarter?: LifeMD, Inc. (NASDAQ:LFMD) posted its quarterly earnings data on Monday, March, 11th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.02. The company earned $44.86 million during the quarter, compared to analysts' expectations of $40.65 million.
What ETF holds LifeMD's stock?: Invesco Dorsey Wright Healthcare Momentum ETF holds 140,399 shares of LFMD stock, representing 0.98% of its portfolio.
What guidance has LifeMD issued on next quarter's earnings?: LifeMD updated its first quarter 2024 earnings guidance on Tuesday, March, 12th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $42.0 million-$43.0 million, compared to the consensus revenue estimate of $42.5 million.
How do I buy shares of LifeMD?: Shares of LFMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LFMD) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial